Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 7/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22793920 | 0.87 | SMN1; SMN2 (0.46) | HRH3SMN1; SMN2EPHX1EPHX2 | |
| SCHEMBL23867015 | 0.84 | GNAO1 (0.58) | GNAO1HRH3GNAI3GNAI1EPHX1 | |
| SCHEMBL13183482 | 0.84 | GNAO1 (0.58) | GNAO1HRH3GNAI3GNAI1SMN1; SMN2 | |
| SCHEMBL23997616 | 0.81 | GNAO1 (0.44) | GNAO1HRH3GNAI3GNAI1SMN1; SMN2 | |
| SCHEMBL3993182 | 0.79 | CACNA2D1 (0.42) | GNAO1HRH3GNAI3GNAI1SMN1; SMN2 | |
| SCHEMBL4031644 | 0.79 | GBA1 (0.42) | GNAO1 | |
| SCHEMBL26480956 | 0.78 | SMN1; SMN2 (0.41) | HRH3SMN1; SMN2EPHX1EPHX2 | |
| SCHEMBL27267481 | 0.78 | NCF1 (0.48) | GNAO1HRH3GNAI3GNAI1SMN1; SMN2 | |
| SCHEMBL7738185 | 0.78 | HSD11B1 (0.47) | HRH3SMN1; SMN2EPHX1EPHX2 | |
| SCHEMBL4036508 | 0.78 | NCF1 (0.48) | GNAO1HRH3GNAI3GNAI1ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638631-B2 | Methylene dipiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2009-12-29 | — | — | US | disclosed |
| EP-1789410-B1 | METHYLENE DIPIPERIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2009-06-17 | — | — | EP | disclosed |
| US-20080108624-A1 | Methylene Dipiperidine Derivatives | GLAXO GROUP LIMITED (GB) | 2008-05-08 | — | — | US | disclosed |
| EP-1789410-A1 | METHYLENE DIPIPERIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006029906-A1 | METHYLENE DIPIPERIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108624-A1 | Methylene Dipiperidine Derivatives | DRD2, DRD4, PNMT | GNAO1 3472/4885HRH3 620/4885GNAI3 2232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.